Loading clinical trials...
Loading clinical trials...
Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Shire
NCT06933472 · Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, and more
NCT03573089 · Kidney Failure, Chronic, Hyperphosphatemia
NCT00506441 · Chronic Kidney Disease, Dialysis, and more
NCT00542815 · Chronic Kidney Disease, Dialysis, and more
NCT05085275 · Anemia, Iron Deficiency, Hyperphosphatemia, and more
Imperial care Dialysis Center
Lynwood, California
Barnett Research and Communications Medical Group
Torrance, California
Western new England Renal & Transplant Associates
Springfield, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions